PMID
int64 27.8M
36.2M
| Title/Abstract
stringlengths 7
10.7k
| MeshTerms
stringlengths 7
104
| SemanticTypes
stringlengths 4
84
|
|---|---|---|---|
34,693,796 | covid behavior belief toward immun among colleg student lima peru introduct peru experienc one highest rate covid popul vaccin colleg student must make decis vaccin base belief knowledg immun purpos studi describ covid behavior belief toward immun among colleg student lima peru method undergradu student universidad maria auxiliadora uma particip descript studi cdc nation hn flu survey adapt measur behavior belief immun covid result student particip studi academ year signific differ identifi take vaccin avail age p gender p marit status p incom p signific associ found particip ethnic locat last vaccin p race reason receiv covid vaccin p conclus peruvian student age elig covid time find prepar academ institut promot educ vaccin age group uniqu barrier receiv health care vaccin | D000086382;D053118 | T047;T005;T067 |
34,693,794 | develop onlin searchabl databas systemat map organis current literatur retent research orrca address recruit retent challeng trial key prioriti method research navig literatur difficult time consum orrca wwworrcaorguk launch free searchabl databas recruit research wide access use support updat systemat review select recruit strategi clinic trial orrca aim creat similar databas map grow volum import retent research | D016206 | T170 |
34,693,792 | bioinformat analysi quercetin octagon lotus screen breast cancer myc cxcl cxcl ef comprehens bioinformat analysi effect molecular screen podophyllum octagon breast cancer treatment use network pharmacolog | D000972;D028141;D001943;D011794 | T191;T121;T002;T109;T127 |
34,693,789 | choos chang analysi scale non inferior trial binari outcom size margin strong influenc requir sampl size non inferior equival trial sometim ignor howev trial binari outcom scale margin risk differ risk ratio odd ratio also larg impact power thus sampl size requir consid sever scale design stage trial sampl size consequ taken account sometim chang scale may need later stage trial exampl event proport control arm turn differ expect also complet trial switch anoth scale sometim made exampl use regress model secondari analysi combin studi result meta analysi requir unifi scale exact consequ switch current unknown | D002986;D012107 | T096;T170;T169;T081;T062 |
34,693,788 | person remot mobil survey adult adhd symptom function pilot studi usabl util pharmacolog monitor valid usabl treatment sensit remot sms base adhd monitor method | D001289;D000697 | T048;T121 |
34,693,786 | dome supramalleolar osteotomi treatment ankl pain oppos coron plane deform ankl lower limb dome type osteotomi power techniqu deform correct limb howev limit inform util dome supramalleolar osteotomi smo ankl joint preserv surgeri studi aim describ techniqu indic dome smo distal tibial malalign | D000842;D000843 | T029;T030 |
34,693,783 | address adultif black pediatr patient emerg depart framework decreas dispar systemat racism structur discrimin unit state factor negat affect health black individu famili one form racism often goe unrecogn yet profound negat impact health safeti black children adultif adultif occur children perceiv treat older implement racism root caus framework identifi way health care provid health care system work dismantl inequ address adultif black children emerg depart ed shift chang polici system environ ed begin recognit blind spot train communic reflect util method identifi adultif racism icd cm diagnosi code z target perceiv advers discrimin persecut assist provid recogn preval racism discrimin reduc harm inequ injustic impact racism black children ed essenti use trauma inform care interact crucial employe ed understand adultif extrem preval hard recogn caus harm health black children famili without conscious effort decreas pervas detriment adultif bias repercuss racism continu perpetu medic mistrust negat health care experi black children famili | D001741;D063505 | T054;T098 |
34,693,782 | covid vaccin accept among client staff homeless shelter detroit michigan februari understand covid vaccin accept among client staff homeless shelter inform public health effort focus communic educ popul covid vaccin thus improv vaccin uptak object studi assess covid vaccin accept uptak among peopl homeless shelter detroit michigan cross section studi conduct februari seventeen homeless shelter survey seven male three malefemal seven women famili shelter client staff age year abl complet verbal survey english translat elig particip individu approach declin leav total sampl client staff particip studi median client staff age year respect particip identifi non hispan black african american sixti one client staff alreadi receiv plan receiv covid vaccin twelv client four staff unsur client five staff plan get vaccin reason hesit concern side effect client seven staff unknown long term health impact client six staff half client alreadi receiv plan receiv vaccin continu effort vaccin educ hesit client staff access vaccin event popul may improv accept uptak | D000086382;D006703 | T047;T098;T095;T067;T033 |
34,693,781 | unilater sudden sensorineur hear loss vertigo first symptom bilater intern auditori canal metastas case report relat report bilater intern auditori canal metastas asymptomat primari pulmonari adenocarcinoma present unilater sudden sensorineur hear loss vertigo report case year old male patient complain sudden hear loss right ear vertigo upon physic examin definit neurolog sign nystagmus observ pure tone audiometri show deaf right ear frequenc high frequenc sensorineur hear loss left ear video head impuls test suggest bilater vestibulopathi magnet reson imag brain gadolinium contrast reveal bilater intern auditori canal enhanc variabl size nodular peripher enhanc lesion cerebrum right cerebellum comput tomograph bronchoscop biopsi identifi asymptomat primari pulmonari adenocarcinoma left upper lobe lung rare report bilater intern auditori canal metastas asymptomat patient primari pulmonari adenocarcinoma initi present symptom unilater sudden sensorineur hear loss vertigo | D006319;D003639 | T033;T047;T184 |
34,693,780 | endoscop transconjunctiv optic nerv sheath fenestr progress idiopath visual field deficit case report intra orbit optic nerv sheath fenestr onsf effect option patient progress vision loss due idiopath intracrani hypertens propos techniqu involv surgic trauma requir disinsert medial rectus muscl thus less invas surgic procedur need feasibl effect techniqu endoscop intra orbit onsf conjunctiv incis present patient progress compromis visual field papilloedema distend subarachnoid space around optic nerv retrobulbar segment optic nerv expos incis avoid manipul later orbit rim bone irrit ciliari microvessel nerv patient regain entir visual field onsf safe effect perform endoscop narrow corridor gain brush away orbit fat minim traction medial rectus muscl small postop wound associ faster easier convalesc less tissu trauma versus convent open approach | D010211;D011559 | T047;T046 |
34,693,779 | diagnost prognost nomogram bone metastasi small cell lung cancer patient bone metastasi bm small cell lung cancer sclc poor prognosi aim identifi predictor prognost factor patient bm sclc construct nomogram predict bm | D008175;D055752 | T191 |
34,693,778 | increas number electrocardiogram find requir addit cardiac examin young athlet coronavirus diseas pandem case seri aim compar result electrocardiogram ecg examin young athlet includ period coronavirus diseas covid pandem special attent wave invers might sign myocard retrospect observ studi review data ecg examin among young athlet age year year set novi sad sport medicin center serbia hypothes young athlet chang ecg asymptomat covid group signific ecg find requir addit cardiac examin accord modern sport cardiolog compar previous year describ one case document asymptomat covid infect wave invers v v number schoolchildren asymptomat covid infect might high class novi sad conduct face face serious risk myocard exist young athlet especi relat covid infect care sport preparticip examin import identifi athlet possibl requir addit test medic care prior return sport | D000086382 | T047;T067 |
34,693,777 | belief legal benefit mental health research mental health pay increas attent influenc social institut subject well life cours yet littl research consid belief promis legal institut may benefici effect well structur equat model longitudin data find suggest belief neutral fair legal institut salutari effect mental health net social econom status across individu wide rang ethnic group combin research sociolog mental health cultur sociolog social psycholog sociolog law extend emerg literatur institut determin mental health includ attent law one central organ institut social life | D005006;D008603 | T041;T098;T102 |
34,693,776 | progress celiac diseas diagnost modal treatment option celiac diseas cd autoimmun disord affect genet predispos individu sensit gluten relat protein affect children adult increas preval older age group adapt innat immun respons play role cd pathogenesi result damag lamina propria deposit intraepitheli lymphocyt propos mechan cd pathogenesi like gastrointestin infect intestin microbiota earli introduct gluten diagnosi cd base clinic symptom serolog test though major case asymptomat small intestin biopsi requir confirm diagnosi celiac diseas general associ autoimmun diseas advis test patient diseas like type diabet mellitus addison diseas thyroid diseas inflammatori bowel diseas autoimmun hepat patient new diagnosi cd requir close follow start treatment see symptom improv check dietari complianc newli diagnos patient advis follow dietitian better understand dietari restrict patient stay symptomat even start treatment due noncompli poor understand diet restrict effect treatment cd gluten free diet work non dietari therapi process medic clinic trial phase | D002446 | T047 |
34,693,775 | network adhd sct symptom emerg adulthood emerg adulthood year transit understudi development period yet littl known specif symptom adhd well relat sct domain may differenti relat one anoth period differ base biolog sex close result align adulthood | D001289;D003072 | T048 |
34,693,774 | reson moment explor socio materi connect artist encount peopl live dementia articl introduc insight new materi feminist theori understand connect basi aesthet analysi artist encount peopl live dementia draw data situat art intervent conduct within reson project residenti care home northern norway research artist health care profession peopl live dementia famili member came togeth co creativ music session analys two reson moment session way abduct process oscil theori written note video record embodi experi field discuss way materi listen group matter come abil connect session base find conclud notion socio materi connect provid entranc point studi differ way relat peopl live dementia enquir relat matter | D001154;D003704;D009146 | T048;T170;T090 |
34,693,773 | california local flavor tobacco sale restrict effect reduc retail avail flavor tobacco product multicompon evalu flavor tobacco appeal new user paper describ evalu result california earli ordin restrict flavor tobacco sale | D005421;D062789 | T131;T120;T073;T109 |
34,693,772 | optim one stage design analysi efficaci expans phase oncolog trial contemporari phase oncolog trial often includ efficaci expans various tumor indic post dose find preliminari anti tumor activ efficaci expans aid gono go decis phase phase initi tumor cohort efficaci expans common analyz independ practic often underpow due small sampl size pool analysi also sometim conduct ignor heterogen anti tumor activ across cohort | D009369;D012107 | T191;T096;T170;T169;T081;T062 |
34,693,771 | effect capsular tension ring implant phacoemulsif postop refract assess refract outcom phacoemulsif pe addit capsular tension ring ctr implant | D002387;D006956;D007910;D018918 | T074;T047;T061 |
34,693,768 | latina communiti evalu cultur adapt conexion program enhanc connect ec evid base intervent promot communic cancer diagnos mother school age children ec valid colleg educ non latina white mother privileg socioeconom status latina research cultur adapt ec latina mother diagnos cancer renam conexion follow cultur adapt guidelin next recommend step engag new consum group latina mother evalu newli adapt educ materi | D006630;D009035 | T092;T098;T099 |
34,693,767 | clinic leadership covid pandem reflect lesson learn covid continu wreak havoc worldwid healthcar system particular challeng personnel shortag resourc insecur mix messag fear name outset thought pandem would short live result enact disast plan hospit autocrat approach alway effect long term servant leadership approach conduc engag team dyad structur support effect leadership challeng time one right approach lead pandem lesson learn pandem applic next pandem occur | D000086382;D007857 | T047;T078;T054;T067 |
34,693,765 | time redefin safeti healthcar throughout covid pandem frontlin healthcar worker around globe provid except patient care despit fear infect shortag staff suppli frustrat tri treat novel pathogen time covid expos deep system risk healthcar team member physic psycholog emot safeti drive burnout crisi level burnout aris emot toll care sick die patient covid also expos flaw health system infrastructur system inequ amplifi covid disproportion impact peopl colour indigen communiti member renew expand definit safeti need restor trust recruit retain individu heal profess enabl care provid greatest skill human ensur well everi person work healthcar collabor ceo divers group health system unit state author draft declar principl expand definit safeti includ safeguard psycholog emot well team member promot health justic declar equiti anti racism core compon safeti ensur physic safeti includ zero harm program elimin workplac violenc physic verbal invit canadian leader embrac concept commit support team member safeti well essenti foundat public health must human healthcar time act | D000086382;D058873 | T047;T067 |
34,693,763 | stakehold involv evalu affect observ percept evalu stakehold group peopl think particip stakehold often involv evalu select specif research question interpret result except topic whether stakehold involv increas use pauciti research exist guid practic regard stakehold | D000073597 | T054 |
34,693,760 | predict ioniz hypocalcemia extern valid ioniz calcium predict model patient covid renal failur ioniz hypocalcemia common critic ill patient covid associ advers outcom previous develop linear model estim ioniz calcium ca adjust total calcium ca three compon anion gap albumin intern valid outperform popular method correct ca albumin alon ct ca diagnos low ca studi sought extern valid ca model hospit covid posit patient | D000086382;D006996;D051437 | T047;T067 |
34,693,759 | stone retropuls caus puls durat adjust holmium laser analysi whole process dynam modifi method introduct stone retropuls shown impact puls durat holmium laser lithotripsi although whole process retropuls troublesom studi develop modifi method analyz retropuls use smartphon video track softwar materi method holmium laser system incorpor short second long puls durat lp second core fiber attach cross section v shape rail submerg tank artifici stone displac linear laser differ combin puls energi frequenc puls durat test least second iphon capabl high definit video video track softwar use analyz stone displac veloc result set displac time graph resembl logarithm growth veloc peak within first second laser higher energi frequenc translat greater displac accompani earlier faster veloc peak laser power constant short puls durat fourth second laser much larger j hz j hz short puls durat sp mm vs mm p discrep offset lp largest stone displac veloc observ j hz sp conclus puls durat play domin role determin stone retropuls veloc long puls decreas retropuls veloc given constant power variabl combin frequenc puls energi contribut signific differ retropuls short puls rather long puls modifi method offer feasibl solut studi stone retropuls laser lithotripsi | D002137;D053844;D017602 | T061;T074;T031;T073 |
34,693,757 | design placebo control random trial anticanc agent ethic consider base review publish trial limit inform exist design placebo control cancer trial systemat review trial publish describ placebo use random trial test anticanc agent analyz strategi increas exposur experiment regimen | D000970 | T121;T109 |
34,693,756 | acut cardiometabol effect brief activ break sit patient rheumatoid arthriti exercis treatment rheumatoid arthriti particip moder vigor exercis challeng patient light intens break sit could promis altern compar acut effect activ break sit moder vigor exercis cardiometabol risk marker patient rheumatoid arthriti crossov fashion women rheumatoid arthriti underw three h experiment condit prolong sit sit min bout moder vigor exercis follow prolong sit ex min bout light intens walk everi min sit br postprandi glucos insulin c peptid triglycerid cytokin lipid classessubclass lipidom blood pressur respons assess muscl biopsi collect follow session assess target proteinsgen glucos area curv auc p insulin auc p c peptid auc p postprandi respons attenu br versus sit wherea c peptid lower ex versus sit auc p il decreas br increas ex sit p p respect il ra increas ex versus br p tnf concentr decreas br versus ex p ex br reduc systol blood pressur p lipidom analysi show lipid classessubclass signific differ condit greater chang observ ex differ observ proteingen express brief activ break sit offset marker cardiometabol disturb may particular use patient may find difficult adher exercis new noteworthi exercis treatment rheumatoid arthriti challeng patient light intens break sit could promis altern find show benefici differenti cardiometabol effect activ break sit exercis patient rheumatoid arthriti break sit main improv glycem inflammatori marker wherea exercis improv lipidom hypotens respons break sit show promis offset aspect cardiometabol disturb associ prolong sit rheumatoid arthriti | D001172;D057185 | T033;T047;T079 |
34,693,755 | energi expenditur due gluconeogenesi patholog condit insulin resist gluconeogenesi gng format glucos noncarbohydr precursor requir adenosin triphosph atp previous studi estim energet cost gng human base theoret calcul rate gng mole oxygen consumpt gng averag oxygen consumpt human studi measur energi expenditur ee due gng estim ee attribut gng patient three insulin resist condit high gng rate insulin receptor pathogen variant lipodystrophi type diabet obes without diabet fraction gng measur incorpor deuterium bodi water newli form glucos endogen glucos product egp glucos appear follow administr h glucos total gng fraction gng egp ee measur indirect calorimetri compar predict ee mifflin st jeor equat ee attribut gng estim use linear regress account age fat free mass ffm ee patient insulin resist signific higher predict mifflin st jeor equat gng correl rest ee ree ee attribut gng patient insulin resist almost one third ree substanti higher theoriz healthi subject find demonstr gng signific contributor ee insulin resist state predict equat may underestim calor need patient insulin resist therefor target calor need account higher ee due increas gng consid energi balanc studi patient insulin resist new noteworthi gluconeogenesi energi requir process upregul diabet contribut hyperglycemia previous studi estim gluconeogenesi account less rest energi expenditur studi estim energi expenditur attribut gluconeogenesi uncommon sever form insulin resist common milder form insulin resist popul gluconeogenesi account almost one third rest energi expenditur substanti higher previous theoriz literatur | D007333 | T046 |
34,693,754 | endotheli dysfunct thrombosi format secret covid world hard battl covid endotheli cell among critic target sar cov dysfunct endothelium lead vascular injuri follow coagulopathi thrombot condit vital organ increas risk life threaten event grow evid reveal endotheli dysfunct consequ thrombot condit associ sever outcom yet fulli clear devast sequel origin direct virus side effect virus induc cytokin storm due endotheli dysfunct plasma level biomark chang relev clinic manifest appear well stabil endotheli integr support function among promis therapeut strategi respiratori covid could call system vascular diseas aspect scrutin detail order reduc relat mortal present investig effect covid endotheli function thrombosi format discuss regard critic player laboratori find clinic manifest suggest therapi present | D001777 | T042 |
34,693,753 | develop novel clinic radiolog risk score predict septic complic urinari decompress patient obstruct uropathi background well defin clinic predictor sepsi upper tract drainag obstruct uropathi lack studi aim develop data driven score predict risk sepsi decompress upper urinari tract materi method complet clinic radiolog data patient enter emerg depart obstruct uropathi submit stentnephrostomi tube decompress evalu charlson comorbid index cci use score comorbid definit sepsi increas sequenti organ failur assess point postop persist elev score addit increas document blood urin cultur descript statist stepwis multivari logist regress model receiv oper characterist analysi perform obtain composit risk score predict risk sepsi surgeri studi approv local ethic commite prot result fifti five patient develop sepsi multivari analysi cci odd ratio confid interv ci maximum bodi temperatur c ci grade iii iv hydronephrosi ci hu dilat collect system ci white blood cell mmc ci c reactiv protein ci independ associ sepsi posit predict valu true sepsi increas increment function number posit variabl rang among patient posit variabl respect conclus risk score identifi accur patient increas risk sepsi urinari decompress obstruct uropathi henc improv clinic manag | D018805;D014551 | T023;T047;T046 |
34,693,752 | contemporari assess econom burden upper urinari tract stone diseas unit state analysi one year health care cost background us health care landscap wit numer chang sinc implement afford care act coupl rise preval upper urinari tract stone diseas sd data econom burden sd period lack provid object studi materi method adult diagnos sd identifi pearldiv marin nation payer databas report reimburs prescript cost health care encount patient undergo oper nonop care identifi time trend annual expenditur evalu multivari analysi evalu determin spend result total billion spent sd manag median overal annual expenditur billion among patient inpati prescript outpati cost account expenditur respect seventi eight percent patient manag nonop total cost billion averag overal cost per encount surgic vs nonsurg care expenditur inpati care decreas signific time expenditur prescript outpati care increas signific multivari analysi higher charlson comorbid index cci associ higher spend associ age insur region vari treatment modal conclus econom burden sd manag substanti domin expenditur nonop manag outpati care expenditur prescript outpati care rise consist predictor higher spend cci spend variat accord demograph clinic geograph factor evid | D014545;D014570 | T047;T031 |
34,693,751 | diagnosi asthma physiolog test small airway function help asthma common chronic heterogen diseas global impact substanti econom cost also associ signific mortal morbid burden undiagnos asthma signific asthma difficult diagnos gold standard test spirometri central diagnos asthma may suffici confirm exclud diagnosi common report spirometr measur forc expiratori volum one second fev forc vital capac assess function larger airway howev small airway dysfunct high preval asthma studi suggest small airway involv one earliest diseas manifest moreov new inhal therapi ultrafin particl specif design target small airway potenti test small airway may accur diagnos earli mild asthma assess respons treatment spirometri furthermor assess techniqu reli forc ventilatori manoeuvr may therefor easier certain group perform review discuss current evid small airway test asthma futur research may need assess util | D001249 | T047 |
34,693,750 | quick effici method generat immunomodulatori mesenchym stromal cell human induc pluripot stem cell mesenchym stromal cell mscs wide investig regen capac anti inflammatori properti benefici immunomodulatori effect across multipl clinic indic nevertheless widespread clinic util limit variabl msc qualiti impact donor age metabol diseas human induc pluripot stem cell hipsc generat readili access donor tissu promis sourc stabl rejuven msc differenti method general requir prolong cultur result low frequenc stabl mscs overcom limit optim quick effici method hipsc differenti footprint free mscs human induc mscs himsc studi method capit synergist action growth factor wnta activin bone morphogenet protein bmp lead enrich msc day treatment himsc demonstr signific upregul mesenchym stromal marker cd cd cd cadherin compar bone marrow deriv mscs bmmscs reduc express pluripot gene octam bind transcript factor oct cellular myelocytomatosi oncogen c myc klf nanog homebox nanog compar hipsc moreov show improv prolifer capac cultur without induc teratoma format vivo osteogenesi chondrogenesi adipogenesi assay confirm abil himsc differenti three differ lineag secretom analys show cytokin profil compar bmmscs encapsul himsc algin bead cocultur osteoarthrit oa cartilag explant show robust immunomodul stimul cell growth proteoglycan product oa cartilag quick effici protocol deriv himsc hipsc encapsul microbead therefor present reliabl reproduc method boost clinic applic mscs | D057026;D059630 | T025 |
34,693,749 | monitor excim laser guid cardiac lead extract uniport video assist thoracoscopi singl center experi though laser guid extract cardiac implant electron devic lead becom routin procedur sever complic associ high mortal report singl center experi use uniport video assist thoracoscopi laser lead extract compar stand alon laser lead extract | D020878;D013906 | T061 |
34,693,748 | impact complex partial nest cluster three arm individu random group treatment trial case studi whope trial particip individu random group treatment trial treat multipl clinician multipl group treatment session throughout trial induc partial nest cluster affect power trial investig issu whole health option pain educ trial three arm pragmat individu random clinic trial evalu whether partial cluster due multipl visit deliv differ clinician whole health team arm dynam particip group due chang group leader andor particip across treatment session treatment deliveri primari care group educ arm may impact power trial also present bayesian approach estim intraclass correl coeffici | D015233;D012107 | T170;T169;T062;T081;T096 |
34,693,747 | plasma atherogen index independ predictor arteri stiff healthi korean plasma atherogen index aip suggest use independ predictor cardiovascular diseas cvds high cv risk patient investig associ aip arteri stiff measur brachial ankl puls wave veloc bapwv healthi adult total healthi subject without metabol cv diseas enrol anthropometr cv risk factor measur aip defin base logarithm ratio concentr triglycerid high densiti lipoprotein cholesterol subject classifi aip quartil gradual deterior metabol paramet increas bapwv across increas aip quartil fulli adjust analysi compar q lowest quartil group odd ratio confid interv increas bapwv higher q q q highest quartil among men q q q among women p trend strong associ aip bapwv higher aip independ predictor increas arteri stiff healthi korean men women aip may simpl screen tool subclin atherosclerosi | D002318;D059289 | T047;T046 |
34,693,744 | use multi sensori environ autist children explor effect control sensori chang multi sensori environ also call sensori snoezelen room room contain equip creat light sound touch experi multi sensori environ often use autist children particular school evid best use investig whether control sensori equip multi sensori environ affect group femal autist children age year behav found autist children could control sensori equip paid attent perform fewer repetit sensori behaviour also use less stereotyp speech produc fewer vocalis show lower level activ behaviour affect find demonstr multi sensori environ use impact behaviour provid control sensori chang autist children may help creat better condit learn | D000067877;D001321 | T048 |
34,693,742 | new view macula densa cell protein synthesi macula densa md cell chief sensori cell type nephron endow uniqu microanatom featur includ high densiti protein synthet organell secretori vesicl basal cell process maculapodia suggest far unknown high rate md protein synthesi studi aim explor rate regul md protein synthesi effect glomerular function use novel transgen mous model newli establish fluoresc cell biolog techniqu intravit microscopi sox tdtomato kidney tissu section propargyl puromycin incorpor base fluoresc imag assay show md cell highest level protein synthesi within kidney cortex follow intercal cell podocyt genet gain function mammalian target rapamycin mtor signal specif md cell md mtor gof mice physiolog activ low salt diet result signific increas synthesi md protein specif includ classic recent identifi md specif protein cyclooxygenas microsom prostaglandin e synthas pappalysin intravit imag kidney use multiphoton microscopi show signific increas affer effer arteriol glomerular capillari diamet blood flow md mtor gof mice coupl elev glomerular filtrat rate present identifi high rate md protein synthesi regul mtor signal novel compon physiolog activ glomerular hemodynam regulatori function md cell remain fulli character new noteworthi studi discov high rate protein synthesi macula densa md cell appli direct imag techniqu singl cell resolut physiolog activ mammalian target rapamycin signal play import regulatori role process new featur novel compon tubuloglomerular cross talk glomerular hemodynam regulatori function md cell futur work need elucid natur patho physiolog role specif protein synthes md cell | D014176 | T044 |
34,693,741 | data monitor committe interim report must get soon current mani data monitor committe report interim review trial progress quit inadequ data monitor committe make inform decis risk benefit immedi serious improv necessari data monitor committe meet ethic clinic scientif respons trial particip investig sponsor particip institut achiev critic goal parti involv data monitor committe process includ sponsor investig data monitor committe member independ statist report group need better understand structur function need data monitor committe content data monitor committe report train modul societi clinic trial avail websit facilit | D026661 | T097 |
34,693,740 | comparison clinicopatholog oncolog outcom transurethr en bloc resect convent transurethr resect bladder tumor systemat review meta analysi network meta analysi focus differ energi sourc introduct hypothes transurethr en bloc tueb bladder tumor offer benefit convent transurethr resect bladder tumor cturbt studi aim compar diseas outcom tueb cturbt focus differ energi sourc method systemat search perform use pubm web scienc databas june studi compar patholog detrusor muscl presenc oncolog recurr rate efficaci safeti serious advers event sae tueb cturbt includ random fix effect meta analyt model bayesian approach network meta analysi use result seven random clinic trial rcts seven non rcts nrct total patient pool month recurr risk ratio rr five four nrcts ci ci respect pool month recurr rrs four seven rcts ci ci respect pool rr sae prolong hematuria bladder perfor seven rcts ci benefit tueb seven rcts n met elig criteria network meta analysi differ month recurr rate hybridknif laser bipolar tueb compar cturbt contrari laser tueb signific associ lower sae compar cturbt surfac cumul rank curv rank analys show high certainti laser tueb best treatment option access endpoint conclus nrcts suggest recurr free benefit tueb compar cturbt rcts fail confirm convers sae consist clinic signific better tueb network meta analys suggest laser tueb best perform compar energi sourc earli find need confirm expand upon | D001749 | T191 |
34,693,739 | synovium human osteoarthrit joint retain chondrogen potenti irrespect age autolog synovium potenti tissu sourc local induct chondrogenesi tissu engin approach repair articular cartilag defect occur osteoarthr aim present studi ascertain whether age human osteoarthrit patient compromis chondrogen potenti knee joint synovium structur metabol stabil transform tissu patient alloc one follow two age categori year year n donor per time point experiment group total number donor synovi biopsi induc vitro undergo chondrogenesi exposur bone morphogenet protein bmp alon transform growth factor tgf alon combin two growth factor week differenti explant evalu morpholog morphometr volum fraction metachromasia sulfat proteoglycan immunohistochem type ii collagen gene express level anabol chondrogen marker well catabol factor real time polymeras chain reaction analysi quantit metachromasia reveal chondrogen differenti human synovi explant induc greatest degre either bmp alon bmp tgf combin compar level two stimul protocol within age categori bmp tgf combin protocol result chondrocyt physiolog size normal human articular cartilag unlik bmp alon stimul result cell size termin hypertrophi stabl gene express level anabol chondrogen marker confirm superior two stimul protocol demonstr hyalin like qualiti generat cartilag matrix gene express level catabol marker remain extrem low data also confirm use experiment vitro studi bovin synovi tissu paradigm human synovi investig data reveal chondrogen potenti human knee joint synovium osteoarthrit patient uncompromis age catabol process potenti synovium base clinic engin repair cartilag tissu use autolog synovium may thus reduc age human patient impact statement data reveal younger older age group alik synovi explant osteoarthrit joint equal well induc undergo chondrogenesi vitro chondrogen potenti human synovium compromis age find impli autolog synovium repres adequ tissu sourc repair articular cartilag clinic practic tissu engin approach human patient suffer osteoarthr independ patient age | D000375;D002358;D010003;D013583 | T023;T047;T040;T033;T024 |
34,693,738 | dust effici novel puls thulium yttrium aluminum garnet laser vs thulium fiber laser background holmium yttrium aluminum garnet laser ho yag still consid gold standard laser lithotripsi larg bodi literatur compar capabl ho yag thulium fiber laser tfls novel puls thulium yttrium aluminum garnet laser p tm yag evalu model compar ho yag term dust perform date studi aim compar p tm yag dust effici chop tfl materi method laser ablat procedur laser devic emit light laser fiber spiral across surfac uniform kidney stone model via softwar reli stone model differ weight dust procedur assess dust effici assess laser devic dust effici various preset laser configur laser fiber motion speed compar laser devic laser configur ident puls energi frequenc keep mind puls durat differ signific addit test laser devic capabl result averag ablat weight across laser configur g standard deviat sd g p tm yag g sd g tfl statist analysi found signific differ ablat weight laser devic u p valu maximum permiss frequenc configur tfl hz result worst overal dust output conclus observ p tm yag dust effici resembl tfl ident puls energi frequenc laser configur ablat effici seem affect laser devic differ puls durat slower laser fiber motion speed result effici ablat use maximum preset frequenc power configur tfl dust effici appear ineffici | D007669;D053685;D053844;D017602 | T074;T047;T073;T061 |
34,693,737 | impact acut care urolog servic timelin qualiti care manag nephrolithiasi background acut care surgeri model led improv outcom emerg surgic condit similar model care implement urolog depart implement acut care urolog acu servic servic evolv aim evalu impact acu model manag nephrolithiasi materi method conduct retrospect review patient urolog consult emerg depart nephrolithiasi requir surgic intervent patient divid three cohort base date consult pre acu phase phase result identifi patient nephrolithiasi requir intervent pre acu phase phase acu implement median time consult definit intervent day acu implement median time intervent decreas day phase p day phase p multivari cox regress hazard definit intervent improv phase hazard ratio hr p phase hr p rate primari definit intervent without initi decompress loss follow also signific improv compar pre acu cohort conclus implement structur acu servic associ improv time treatment patient acut nephrolithiasi well increas primari definit intervent improv follow care model care potenti improv patient outcom nephrolithiasi acut urolog condit | D007669;D053040;D014572 | T091;T047 |
34,693,736 | occup therapi emerg depart patient frailti unschedul return visit background occup therapi facilit care complex frail emerg depart ed patient may unschedul return visit urv purpos determin preval frailti amongst ed patient refer occup therapi frailti affect rate reason urv method mix method health record review conduct older adult refer ed base occup therapi program find patient frail patient discharg home urv within day differ urv rate frail non frail popul provid occup therapi educ reduc frequenc urv frail patient complex reason urv includ function socialenvironment safeti concern andor failur thrive occup therapi ed patient typic vulner moder frail depend activ daili live complex implic ed base occup therapist must awar patient frailti risk urv | D000073496;D009788 | T033;T046;T184;T061 |
34,693,735 | ex vivo renal stone dust impact laser modal ureter access sheath suction total stone clearanc introduct object convent renal stone dust challeng holmium ho yag laser holmium mose effect ho yag mose fail uniform produc fragment ie dust superpuls thulium fiber laser stfl may effect render urolith dust may thus improv stone free rate accord perform ex vivo evalu three laser modal assess stone fragment stone clearanc method seventi two ex vivo porcin kidney uret model divid group laser type ho yag ho yag mose stfl ureteroscop without appli suction presenc absenc f ureter access sheath ua calcium oxal stone preweigh implant kidney via pyelotomi stone treat w use dust set j hz ho yag j hz ho yag mose j hz stfl minut stone basket perform kidney bivalv residu fragment collect dri weigh siev determin fragment size stone clearanc result initi stone mass mg procedur time second laser energi expenditur kj similar group greatest stone clearanc seen stfl suction ua compar convent techniqu ho yag suction ua p use stfl provid greater stone clearanc ho yag ho yag mose aspir improv stone clearanc stfl p ho yag ho yag mose consist creation smaller fragment stfl presenc f ua improv stone clearanc scenario p conclus ex vivo studi stone clearanc optim follow condit stfl f ua aspir combin result stone fragment clear remain fragment mm scenario deploy f ua improv stone clearanc | D007669;D053844;D017602;D014513;D014514 | T047;T023;T073;T074;T061 |
34,693,734 | redistribut outpati oncolog surgic specialti referr covid initi report signific wors outcom cancer patient covid led guidelin triag surgic cancer treatment sought evalu effect covid pandem oncolog surgic specialti referr | D001071 | T058;T052;T170;T079 |
34,693,733 | hyaluron acid function hybrid gelatin poli l lactid scaffold tunabl hydrophil studi describ product hybrid gelatin poli l lactid electrospun scaffold whose hydrophil control bind increas concentr hyaluron acid ha show cross link advantag coat aim function scaffold ha describ scaffold structur mimick complex extracellular matrix excit second harmon generat produc signal typic collagen contain biolog fiber fluoresc lifetim imag microscopi flim use marker independ monitor growth human dermal fibroblast electrospun scaffold use reduc phosphoryl nicotinamid adenin dinucleotid target benefit differ fluoresc lifetim polym endogen cellular fluorophor abl distinguish separ signal produc cell signal generat electrospun scaffold flim allow detect metabol differ cell seed ha function scaffold compar cell cultur nonfunction control scaffold | D005780;D006820 | T116;T121;T109;T123;T122 |
34,693,731 | target activ g protein coupl receptor mediat ca signal drive enhanc cartilag like matrix format intracellular calcium ca signal critic regul chondrogenesi chondrocyt differenti cartilag develop calcium ca signal known direct process govern chondrocyt gene express protein synthesi cytoskelet remodel cell fate control chondrocytechondroprogenitor ca signal attempt mechan andor pharmacolog activ endogen ca signal transduc howev approach lack specif andor precis regard ca activ mechan synthet signal platform permit precis select ca signal transduct improv dissect role ca signal play chondrocyt behavior one platform chemogenet dreadd design receptor exclus activ design drug hmdq activ ca signal via g q plc ip er pathway upon clozapin n oxid cno administr previous demonstr hmdq abil precis synthet initi robust ca transient oscillatori ca signal chondrocyt like atdc cell investig effect long term cno stimulatori cultur hmdq ca signal dynam prolifer protein deposit atdc cultur long term cultur repeat cno stimul modifi tempor dynam hmdq ca signal increas cell prolifer enhanc matrix product cno dose frequenc depend manner trigger format cell condens develop align anisotrop neotissu structur rich cartilagin proteoglycan collagen absenc differenti induc studi demonstr g q g protein coupl receptor gpcr mediat ca signal involv chondroprogenitor prolifer cartilag like matrix product establish hmdq power tool elucid role gpcr mediat ca signal chondrogenesi chondrocyt differenti impact statement target activ intracellular calcium signal gain attent cartilag tissu engin adjuv approach present studi demonstr activ hmdq engin chemogenet activ g q pathway ip mediat intracellular calcium signal drive acceler develop mesenchym like cell condens cartilagin neotissu format chondrocyt like cell cultur vitro without requir differenti factorsinduc outcom highlight potenti targetedsynthet g q pathway activ specif use novel chemogenet approach enhanc studi chondrocyt physiolog improv cartilag tissu engin approach | D002118;D020219 | T042;T121;T196;T123 |
34,693,730 | featur select critic year prognosi advanc stage high grade serous ovarian cancer use machin learn accur predict patient prognosi especi use select best treatment protocol machin learn serv purpos make predict base upon generaliz clinic pattern embed within learn dataset design studi support featur select year prognost period compar perform sever machin learn predict algorithm accur year prognosi estim advanc stage high grade serous ovarian cancer hgsoc patient | D000069550 | T066 |
34,693,727 | mirna express profil hiv pathogenesi diseas progress respons treatment systemat review aim systemat review conduct identifi associ mirna express hiv pathogenesi progress treatment method search articl conduct medlin cochran central regist control trial global health result articl includ due heterogen hiv phenotyp harmon base key progress paramet propos hsa mir famili hsa mir b p hsa mir p frequent differenti express hiv direct comparison studi possibl due heterogen biolog sampl mirna analysi techniqu conclus first attempt systemat identifi mirna differ express well defin patient phenotyp could repres help way increas general knowledg field | D005786 | T045 |
34,693,726 | patient experi telemedicin hiv care first covid wave atlanta georgia explor experi telemedicin among person hiv pwh first wave coronavirus diseas covid pandem conveni sampl adult year receiv care urban clinic atlanta invit particip patient complet structur survey assess use qualiti satisfact concern telemedicin servic telephon call receiv first wave covid pandem march may demograph plasma hiv rna cd cell count data obtain medic chart abstract bootstrap test chi squar test use examin differ patient experi age sex race pwh contact complet survey median age year men black viral suppress median cd count cellsl main hiv care disrupt experienc delay follow visit difficulti get viral load measur difficulti access antiretrovir therapi particip rate qualiti median score use median score satisfact median score telemedicin high howev patient express concern provid abil examin lack laboratori test women concern provid abil examin vs p safeti person inform vs p compar men age race differ observ although pwh general satisfi telephon base telemedicin concern use notabl particular among women futur hiv telemedicin model address | D000086382;D015658;D017216 | T058;T047;T067 |
34,693,725 | meta analys deflazacort versus prednisoneprednisolon patient nonsens mutat duchenn muscular dystrophi aim compar efficaci deflazacort prednisoneprednisolon provid clinic meaning delay loss physic mileston patient nonsens mutat duchenn muscular dystrophi materi method placebo data phase iib clinicaltrialsgov identifi nct act dmd clinicaltrialsgov identifi nct ataluren nonsens mutat duchenn muscular dystrophi clinic trial retrospect combin meta analys intent treat popul chang baselin week min walk distanc mwd time function test result signific improv chang min walk distanc deflazacort versus prednisoneprednisolon least squar mean differ ci p signific clinic meaning improv stair climb stair descend deflazacort versus prednisoneprednisolon conclus deflazacort provid clinic meaning delay loss physic mileston week compar prednisoneprednisolon patient nonsens mutat duchenn muscular dystrophi | D018389;D020388 | T049;T086;T047;T045 |
34,693,723 | transves approach robot assist bladder diverticulectomi surgic techniqu outcom object treatment bladder diverticula may becom necessari case incomplet bladder empti recurr urinari tract infect uti bladder outlet obstruct present simultan desobstruct procedur perform video present techniqu transves approach robot assist bladder diverticulectomi rabd discuss outcom patient surgic procedur retrospect analyz outcom patient underw transves rabd march may olv hospit aalst retrograd fill cystotomi perform orific identifi bladder diverticulum observ mucosa cover diverticular neck incis plane mucosa musculari identifi mucosa separ surround structur base diverticulum transect use cauteri defect close barb sutur result median age year interquartil rang iqr number diverticula remov rang ten patient treat diverticulectomi alon underw simultan adenomectomi radic prostatectomi median oper minut iqr median estim blood loss ml iqr median catheter time day iqr median hospit time day iqr one patient develop urinari leakag cathet remov one patient develop uti median follow month iqr late postop complic relaps record averag postvoid residu ml iqr median declin ml iqr conclus transves approach rabd safe reliabl techniqu give advantag quick local diverticulum orific direct access prostat simultan desobstruct necessari catheter time short relaps observ | D004240;D065287;D012371 | T190;T090;T047;T061 |
34,693,721 | hurdl wide implement photoimmunotherapi near infrar photoimmunotherapi nir pit molecular target treatment cancer achiev inject conjug irdyedx ir water solubl silicon phthalocyanin deriv near infrar monoclon antibodi target cancer cell antigen nir pit high specif treatment side effect result rapid immunogen cell death despit effect innov therapi challeng prevent full implement clinic practic includ limit near infrar light penetr select target concern tumor lysi syndrom drug cost howev nir pit approv regulatori author japan allow explor mitig challeng maxim benefit treatment modal | D007167;D007259;D010789 | T070;T061 |
34,693,718 | reconstruct deminer dentin matrix via rapid deposit caf nanoparticl situ promot dentin bond dentin bond base wet bond techniqu fundament techniqu use daili clinic tooth restor fixat clinic treatment tooth relat diseas limit bond durabl led insuffici adhes infiltr deminer dentin dd matrix biggest concern contemporari adhes dentistri studi propos high hydrat noncollagen protein ncp form interfaci microenviron dd matrix root caus problem meanwhil endogen phosphat group ncps use pseudonuclei rapid induc format amorph caf nanoparticl situ interfaci microenviron dd matrix thus reconstruct novel porous structur mark facilit infiltr dentin adhes dd matrix also endow dd matrix anticollaps capabl water evapor whether use wet bond air dri mode bond effect great promot month bond strength twice correspond control group suggest nanoreinforc dd matrix elimin depend bond effect moistur status dd surfac control experi dentist consequ bond strategi great improv bond durabl also overcom technic sensit bond oper total etch bond pattern exhibit potenti promot dentin bond great signific dentistri | D014089 | T061 |
34,693,717 | vitro vivo studi reveal hesperetin glucosid natur occur monoglucosid exhibit strong anti inflammatori capac hesperetin glucosid hes g natur occur flavonoid monoglucosid citri reticulata pericarpium exhibit relat high biolog activ explor anti inflammatori capac dietari hes g lipopolysaccharid lps stimul raw macrophag dextran sodium sulfat dss induc coliti mice use vitro vivo inflamm model result show hes g signific restor cellular metabol disord inflamm lps stimul raw macrophag vivo studi dietari hes g mgkg bodi weight mark allevi inflammatori status dss induc coliti mice manifest recov colon length cm histopatholog chang mrna level colon inflammatori factor includ tnf il furthermor dietari hes g profound regul gut microbiota composit includ phyla bacteroidet cyanobacteria desulfobacterota deferribacter genus enterorhabdus prevotellacea gastranaerophilal enterococcus intestinimona ruminococcacea eubacterium cecal content also especi adjust co metabolit short chain fatti acid indol metabolit indol propion indol acet acid mark alter dss treatment mice find demonstr hes g strong anti inflammatori activ vitro vivo potenti prevent therapeut effect chronic inflamm diseas | D003092 | T047 |
34,693,710 | dual factor synergist activ esipt base probe differenti fluoresc signal simultan detect naphthyl acet acid naphthyl acet esteras naphthyl acet esteras nae acid naphthyl acet esteras ana class special esteras import lymphocyt type immunocompet monitor simultan detect nae ana becom target effect improv accuraci lymphocyt type therefor develop dual factor synergist activ esipt base probe hbt na detect nae ana sensit rapid simultan differenti manner hbt na exhibit differenti fluoresc signal output toward small chang nae ana activ hbt na display weak fluoresc signal nm ph rang howev interact nae u ph fluoresc intens nm enhanc linear within f nm f nm c nae r furthermor hbt na emit ratiometr fluoresc signal f nm f nm ana u ph within min exhibit good linear relationship f nm f nm c ana r differenti fluoresc signal use simultan detect activ nae ana solut complex live organ import base differenti fluoresc signal toward nae ana lymphocyt b lymphocyt could success type differenti among nontyp lymphocyt facilit real time evalu immun function use flow cytometri henc hbt na could use ultrasensit detect enzym activ nae ana real time precis type lymphocyt monitor immunocompet | D009283;D013601 | T025;T116;T126 |
34,693,705 | recommend antibiot select sever nosocomi infect sever infect evolut sepsi becom preval everi day among lead caus critic ill mortal proper manag crucial improv prognosi document address three essenti point signific impact object earli recognit patient sepsi criteria b identif patient suffer infect high risk progress sepsi c adequ select optim initi antimicrobi treatment | D000900;D003428 | T195;T047;T121 |
34,693,704 | risk cours covid patient parkinson diseas articl provid overview data impact parkinson diseas risk infect cours covid also assess possibl pathogenet relationship sar cov virus covid pd penetr central nervous system sar cov caus neurolog symptom also exacerb cours exist neurolog diseas impact parkinson diseas risk infect cours covid controversi howev number author support opinion pd anti risk factor develop covid associ pathogenesi diseas use antiparkinsonian drug particular amantadin clear data indic higher risk infect higher sever covid patient pd contrari experiment clinic data suggest possibl modifi role synuclein antiparkinsonian drug | D000086382;D010300 | T047;T067 |
34,693,703 | featur patient manag traumat brain injuri aim studi consid featur pathogenesi diagnosi therapi traumat brain injuri tbi viewpoint neurologist mechan emerg injuri central nervous system includ neuro inflamm oxid stress patient tbi correl clinic manifest sever tbi discuss special attent paid descript certain tbi consequ eg structur drug resist epilepsi post traumat stress disord provid evid difficulti lesser avail rehabilit program patient tbi covid pandem one mention need administr mexidol antioxidantantihypox drug complex therapi tbi patient period covid pandem role neurologist manag tbi patient still increas especi outpati treatment stage carri therapi medic rehabilit program | D000070642;D000086382;D013313 | T048;T047;T037;T067 |
34,693,702 | newer antipsychot cariprazin reagila perspect use differ stage schizophrenia therapi cariprazin newer rd generat antipsychot act partial agonist dopamin receptor uniqu higher affin receptor review articl summar key data preclin clinic studi cariprazin includ pharmacodynam pharmacokinet clinic efficaci safetyaccept acut short term long term mainten relaps prevent therapi patient schizophrenia efficaci safeti cariprazin patient schizophrenia predomin negat symptom resist previous antipsychot therapi discuss well | D014150;D012559 | T039;T121;T048 |
34,693,701 | oxid stress schizophrenia promis target psychopharmacotherapi dopamin receptor blocker use psychopharmacotherapi schizophrenia despit activ search altern pharmacolog agent lot research howev studi concern molecul somehow affect various neurotransmitt receptor addit various anti inflammatori drug studi quit activ time attempt correct oxid stress given signific less attent although emerg latter facilit complet differ pathophysiolog process environment factor associ develop schizophrenia nmda receptor blockag vitamin defici social isol chronic stress adolesc inflamm perinat infect etc ultim lead occurr oxid stress howev signific differ sever process depend stage cours schizophrenia probabl partial explain heterogen result studi oxid stress biomark disord order overcom methodolog problem seem promis conduct doubl blind studi effect antioxid schizophrenia select group patient take account stage disord level certain biomark oxid stress f isoprostan oxodg oxoguo optim pharmacolog agent studi n acetylcystein due posit result previous studi melatonin antioxid uniqu activ profil | D012559 | T048 |
34,693,700 | cerebrovascular diseas neurocognit impair intern classif diseas th revis section diseas nervous system propos distinguish cerebrovascular disord neurocognit impair correspond discirculatori encephalopathi dep chronic cerebr ischemia cci accept countri also vascular cognit impair terminolog preval risk factor patholog basi diseas discuss particular multipl infarct strateg infarct cerebr small vessel diseas specif microangiopathi intracerebr hemorrhag global hypoperfus post stroke cognit impair discuss detail articl present relev data pathogenesi diseas highlight issu clinic neuroimag diagnost base data present articl conclud diagnosi dep cci base presenc cerebrovascular diseas neurocognit impair impli verif vascular cognit impair reliabl neuroimag sign cerebrovascular patholog exclud caus earli diagnosi effect treatment cerebrovascular diseas neurocognit impair dep cci becom increas import sinc treatment slow progress diseas lead decreas incid stroke dementia | D002561;D015140;D020521 | T047 |
34,693,699 | new treatment option piriformi syndrom paper discuss modern approach diagnosi manag patient piriformi syndrom epidemiolog data preval syndrom neurolog practic present anatom featur region lead format piriformi syndrom describ detail author provid diagnost criteria base neurolog examin manual muscl test discuss differenti diagnosi piriformi syndrom new possibl treat syndrom use fix combin diclofenac orphenadrin regist russian feder drug intraven infus neodolpass discuss detail author cite materi work clinic case manag patient piriformi syndrom use neodolpass analyz | D055958 | T047 |
34,693,698 | explod head syndrom explod head syndrom eh paroxysm sensori parasomnia character sensat loud nois explos head wake sleepsleep wake cycl popular explan condit decreas reticular format activ transit wake sleep author present review literatur diagnosi treatment eh clinic observ patient classic sign | D020447;D012893 | T048;T047;T184 |
34,693,697 | case report neuroacanthocytosi associ compound mutat vpsa gene neuroacanthocytosi group neurodegen diseas manifest combit neurolog symptom often choreic hyperkinesi presenc increas number acanthocyt erythrocyt horn peripher blood group includ chorea acanthocytosi macleod syndrom pantothen kinas associ neurodegener huntington like diseas type rare diseas articl present genet confirm clinic case chorea acanthocytosi associ compound mutat vpsa gene discuss detail stage diagnost search present algorithm examin patient chorea | D054546 | T047 |
34,693,696 | guillain barr syndrom cranial nerv damag complic covid articl present clinic exampl guillain barr syndrom predomin involv cranial nerv develop covid comprehens clinic laboratori diagnost includ examin cerebrospin fluid electromyographi examin possibl etiolog infecti agent carri cours pathogenet therapi use form plasmapheresi session support therapi good clinic effect obtain moment case develop guillain barr syndrom new coronavirus infect describ peculiar case develop clinic pictur insuffici predomin cranial nerv subclin involv nerv extrem | D000086382;D020275 | T047;T067 |
34,693,695 | histori format view schizotyp disord childhood articl reflect stage develop view schizotyp disord std adult children prenosolog period present shown recognit major psychiatrist concept earli dementia propos e kraepelin gradual recognit singl essenc schizophrenia childhood adulthood differ specif clinic manifest differ age period studi variant schizophrenia without fatal outcom dementia led isol sluggish schizophrenia includ childhood begin work e bleuler differ approach studi interpret sluggish schizophrenia russian european american psychiatri led isol stes framework person disord describ three main concept exist present stage research present std consid independ diseas spectrum schizophren disord one type person deviat high degre vulner develop schizophrenia one form diseas | D011570;D012559;D012569 | T097;T091;T048 |
34,693,694 | healthcar russia today epileptolog servic examin state epileptolog servic russia conduct survey epileptologist work differ region russian feder | D000927;D004827 | T033;T047;T121 |
34,693,693 | platelet glutathion reductas glutathion transferas elder patient depress compar activ platelet glutathion reductas gr glutathion transferas gst elder patient depress control group identifi possibl relationship activ enzym clinic paramet diseas | D003863;D005982 | T048;T126;T116;T184 |
34,693,692 | innov technolog assess level complianc mental ill peopl develop technolog evalu indic patient complianc take account clinic socio demograph psycholog characterist patient characterist famili environ well factor psychiatr care base appropri complianc algorithm model | D028642;D012559 | T048;T101 |
34,693,691 | effect oxypyridin succin acid deriv time reduct anxieti depress symptom alcohol withdraw treatment compar effect oxypyridin succin acid deriv emoxypin reamberin mexidol time reduct anxieti depress symptom standard treatment alcohol withdraw syndrom aw | D003863;D019802 | T048;T121;T184;T109 |
34,693,690 | chang adipokin blood patient first episod schizophrenia treatment haloperidol risperidon studi plasma adipokin adiponectin leptin adipsin patient first episod schizophrenia treat haloperidol risperidon | D014150;D012559 | T039;T121;T048 |
34,693,689 | effect use drug recognan citicolin state higher mental function patient mild cognit impair aim observ program studi effect use drug recognan citicolin state higher mental function memori attent visual motor coordin dynam praxi verbal think imagin patient mild cognit impair | D060825;D018697;D004364 | T048;T121 |
34,693,688 | studi effect neuroprotect therapi restor motor function patient acut period ischem stroke purpos work studi effect neuroprotect therapi cellex featur recoveri movement disord patient acut period ischem stroke | D002545;D000083242;D020521;D000071939 | T047;T061;T046 |
34,693,687 | effici applic miorelax lower cross myofasci syndrom evalu efficaci drug tolperison calmirex patient inferior cross syndrom background standard therapi | D009209;D014049 | T047;T121;T184;T109 |
34,693,686 | assess efficaci ethoxidol treatment patient chronic cerebr ischemia evalu clinic effect ethylmethylhydroxypyridin malat ethoxidol patient chronic cerebr ischemia outpati practic | D002545;D060825 | T048;T047;T046 |
34,693,685 | multicent studi influenc differ kind carotid endarterectomi cours resist arteri hypertens analyz dynam systol blood pressur sbp result various type carotid endarterectomi cee patient resist arteri hypertens rah | D016893;D016894;D006973 | T047;T061;T020 |
34,693,684 | influenc parasomnia clinic function characterist extrapyramid disord compar clinic function featur essenti tremor et parkinson diseas pd without rapid eye movement rem sleep behavior disord rbd | D010300;D020187;D012893 | T048;T047 |
34,693,683 | doomsday delus religi content apocalypt version defin psychopatholog phenomenolog characterist apocalypt variant end world delus religi content ewdrc schizophrenia identifi featur clinic dynam delusion disord interact delusion behavior patient | D011618;D012559 | T048 |
34,693,680 | telemedicin surgeri covid pandem enough aim systemat review report analyz impact telemedicin surgic practic covid pandem mani author posit pandem urg high implement telemedicin servic even surgic specialti howev impact chang clinic practic variabl report util general surgeri uncertain | D000359;D000086382;D013502;D017216 | T058;T091;T047;T067 |
34,693,675 | easi use score predict clinic relev postop pancreat fistula distal pancreatectomi postop pancreat fistula popf common serious complic distal pancreatectomi dp effect accept score predict occurr clinic relev cr postop pancreat fistula popf exist | D010180;D010185 | T047;T061 |
34,693,674 | robot esophagomyotomi achalasia technic note review literatur treatment achalasia undergon continu evolut advanc technolog sinc begin new millennium employ robot led technic facilit execut myotomi consequ improv outcom decreas periop morbid | D004931;D000074434;D010535 | T047;T060;T061 |
34,693,672 | inflammatori nutrit biomark predictor non resect earli recurr pancreat periampullari cancer pancreat tumor consid resect preoper stage unresect surgic explor moreov patient subject tumor resect earli recurr | D000230;D004379;D010190 | T191 |
34,693,670 | patient engag system redesign team process social ident studi demonstr patient role system redesign team reflect continuum involv influenc research show process patient move continuum effect engag within redesign project | D010358;D012933 | T058;T080;T054;T081 |
34,693,669 | role support need nurs deliv palliat end life care coronavirus diseas covid pandem led signific increas demand palliat end life care particular communiti furthermor palliat end life care servic face grow pressur due increas number older peopl increas preval chronic ill palliat end life care provid sole specialist need integr mainstream healthcar nurs role support patient life limit condit famili provid term generalist palliat care howev nurs may feel unprepar unsupport lack confid skill role articl explor definit palliat end life care well chang challeng servic provis brought covid pandem also consid nurs specialis area practic support care effect patient life limit condit famili notabl workforc develop initi train programm clinic supervis could increas skill nurs workforc also improv patient care | D024802 | T054 |
34,693,668 | open sourc modular framework autom pipet imag applic number sampl biolog experi continu increas complex protocol human error mani case lead suboptim data qualiti henc difficulti reproduc scientif find laboratori autom allevi mani problem precis reproduc machin readabl protocol instrument general requir high front invest due lack open applic program interfac api notori difficult scientist custom control outsid vendor suppli softwar autom high throughput experi demonstr interdisciplinari research life scienc replic modest budget use open tool ensur reproduc combin tool openflexur opentron imjoy uc autom sampl prepar imag pipelin easili replic establish mani laboratori well educ context easi understand algorithm easi build microscop addit creation feedback loop later pipet imag step depend analysi previous acquir imag enabl realize fulli autonom smart microscopi experi document sourc file public avail prove concept smart lab autom use inexpens open tool believ democrat access power repeat autom experi | D000465;D012984 | T170;T073;T090 |
34,693,666 | field guid print optic microscopi life scienc maker movement reach optic lab empow research creat modifi microscop design imag accessori print disrupt impact field improv access fabric technolog addit manufactur approach particular use rapid low cost prototyp allow unpreced level product access inexpens microscop educ flypi high complex robot microscop openflexur print pave way democrat technolog promot collabor environ research design easili share hold uniqu possibl extend open access concept knowledg technolog allow research everywher use extend model structur present review addit manufactur applic optic microscopi life scienc guid user new excit technolog provid start point anyon will employ versatil power new tool | D001690;D008853 | T059;T090 |
34,693,665 | hemagglutinin nanoparticul vaccin control photochem immunomodul pathogen influenza specif immun recent viral infecti diseas includ covid influenza subject major concern worldwid one strategi address concern focus nasal vaccin great potenti achiev success immun via safe easi afford approach howev convent nasal vaccin major limit result fast remov pass nasal mucosa mucociliari clearanc hinder effect herein nanoparticul vaccin nanovac exhibit photochem immunomodul constitut new self assembl immun system photoactivat polymer adjuv influenza virus hemagglutinin effici nasal deliveri antigen specif immun pathogen influenza virus describ nanovac increas resid period antigen enhanc spatiotempor photochem modul nasal caviti consequ photochem immunomodul nanovac success induc humor cellular immun respons follow stimul matur dendrit cell plasma cell memori b cell cd cd cell result secret antigen specif immunoglobulin cytokin cd cell notabl challeng influenza virus nasal immun nanovac demonstr robust prevent viral infect thus newli design vaccin system serv promis strategi develop vaccin activ current hazard pathogen outbreak pandem | D008027 | T070 |
34,693,664 | ocular express cyclin depend kinas patient prolif diabet retinopathi inhibit peroxisom prolifer activ receptor gamma ppar phosphoryl mediat cyclin depend kinas cdk one main mechan action antidiabet drug studi analyz ocular express activ cdk patient prolif diabet retinopathi pdr | D003920;D003930 | T047 |
34,693,660 | parallel develop vascular neural system signal pathway futur perspect regen medicin neurovascular disord involv vascular nervous system common research disord usual focus either vascular nervous compon without look interact adopt neurovascular perspect essenti improv current treatment therefor compar molecular process known involv system separ provid insight promis area futur research sinc develop regener share mani mechan compar signal molecul involv develop vascular nervous system shed light common reveal process yet studi regen perspect yet hold great potenti henc review discuss compar process involv develop vascular nervous system order provid overview molecular mechan promis regard treatment neurovascular disord vascular endotheli growth factor semaphorin ephrin found hold potenti fibroblast growth factor bone morphogen protein slit sonic hedgehog shown particip develop vascular nervous system yet studi neurovascular level therefor special interest futur research | D015398 | T043;T044 |
34,693,656 | risk factor surgic complic anatom lung resect era vat era aim studi identifi risk factor surgic complic anatom lung resect era video assist thorac surgeri vat enhanc recoveri surgeri era | D000080482 | T061 |
34,693,655 | obes cancer death white black adult prospect cohort studi studi aim determin whether race modifi associ obes cancer death | D009369;D044465 | T191;T098 |
34,693,654 | map evid base practic research field nurs bibliometr analysi evid base nurs practic increas rapid health nurs literatur holist imag evid base nurs research need address evid base studi avail inform nurs | D000086382;D015399 | T062;T047;T067 |
34,693,650 | media intervent program reduc unrealist optim bias link unrealist optim well health unrealist optim tendenc perceiv oneself safer other situat equal threaten everybodi reduc fear bias boost one well howev also deterr one health three experi run mix design particip elimin unrealist optim measur two item probabl covid infect oneself other within subject toward probabl covid infect via articlesvideo subject factor creat manipul ostens daili newspap articl describ peopl dilig follow medic recommend experi video show peopl follow recommend experi reduc unrealist optim third experi includ articl video replic result result appli strategi written video communic use govern public health agenc best practic concern covid also subsequ public health threat promot proactiv optim healthi function individu | D000086382 | T047;T067 |
34,693,649 | correl ct valu bone miner densiti elder chines patient proxim humer fractur investig correl comput tomographi ct valu bone miner densiti bmd elder chines patient proxim humer fractur | D015519 | T081;T201 |
34,693,647 | analysi movement live broiler guangxi china implic avian influenza control chines provinc daili updat databas live anim movement howev data effici util support intervent control hn avian influenza base offici record studi assess spatio tempor pattern live broiler move within guangxi year month network analyz inter intra provinci movement respect approxim movement occur involv transport million live broiler guangxi although guangxi export provinc china inter provinci movement occur three border provinc within guangxi counti high connect live broiler movement creat condit rapid virus spread throughout provinc interest peak movement chines lunar new year celebr late januari observ studi like due hn relat control measur constrain live bird trade intra inter provinci movement march signific higher month year suggest dramat price chang may influenc movement network reshap risk pathway howev despit variat small proport counti less exportingimport inter intra provinci movement remain throughout year intervent particular surveil improv biosecur target counti thus like effect avian influenza risk mitig implement indiscrimin addit simul demonstr target counti accord degre between movement network would effici way limit diseas transmiss via broiler movement studi find provid evid support design risk base control intervent hn avian influenza virus broiler valu chain guangxi | D064766;D005585 | T047;T005 |
34,693,644 | introduct prefer report item systemat review meta analys implic research synthesi methodologist systemat review report complet accur user interpret apprais review find appropri commentari describ key featur major updat prefer report item systemat review meta analys statement prisma discuss implic research synthesi methodologist | D057189;D011643 | T170;T057 |
34,693,643 | health impact climat chang gender divers popul scope review determin known climat chang health effect gender divers gd popul identifi gap research practic educ polici | D057231;D004190 | T070;T067 |
34,693,641 | vaccin induc immun thrombot thrombocytopenia vitt updat diagnosi manag consid differ resourc vaccin induc immun thrombot thrombocytopenia vitt rare sever immunolog reaction non replic adenovir vector base covid vaccin extrem activ platelet coagul system lead high risk death venous arteri thrombosi secondari hemorrhag public clinician awar reduc mortal vitt near world health organ provid guidelin juli diagnosi manag vitt also call thrombosi thrombocytopenia syndrom tts sinc juli new clinic relev inform becom avail updat summar author inform process recommend low resourc environ provid new avail evid vitt empow clinician recogn vitt earli effect diagnos treat disord reduc morbid mortal strong encourag product clear manag pathway primari care set hospit set | D000086382;D013921;D013927;D014612 | T116;T047;T121;T129;T046;T067 |